BioInsights - Accelerating cell therapy discovery & development with non-viral gene engineering
Jun
16
2022
On demand

Accelerating cell therapy discovery & development with non-viral gene engineering

Sponsor
Accelerating cell therapy discovery & development with non-viral gene engineering

Gene engineering of immune cells has become a powerful tool for creating cellular therapies. Currently, this critical step is primarily performed using virus-based gene delivery systems (e.g. lentivirus). However, virus-based engineering methods are plagued with long lead times, inconsistent batches, low cargo capacity, and high costs.

Recently, advances in non-viral gene engineering methods, including transposon-based systems, have provided developers with an alternative gene engineering method that addresses these limitations. Utilizing a “cut-and paste” method of gene delivery, transposon-based systems are capable of stable genomic integration. TcBuster™ is one such transposon-based system and in this webinar we will present data demonstrating both T cell and NK cell gene editing using the technology.

How the mechanism of transposon-based gene engineering systems address the current challenges virus-based systems face What is TcBuster and how does it work How TcBuster compares to other delivery platforms for primary immune cells How TcBuster can be adopted into your pipeline as a research use or GMP compliant system

David Hermanson, Ph.D.

Senior Manager of R&D Applications, Cell and Gene Therapy, Bio-techne

David is the Senior Manager of R&D Applications in Cell and Gene Therapy at Bio-Techne. He works with Bio-Techne’s suite of cell and gene therapy products to establish appropriate protocols and workflows for the modification of immune cells include CAR T and CAR NK cell workflows. His career has focused on non-viral gene editing of T and NK cells using transposon systems and continues to drive the adoption of TcBuster™ for cell therapy.

Xiaobai Patrinostro, Ph.D.

Manager of Genome Engineering Services, Cell and Gene Therapy, Bio-techne

Xiaobai Patrinostro is the Manager of Genome Engineering Services in Cell and Gene Therapy at BioTechne. Xiaobai received her PhD in Molecular Biology and Biochemistry from the University of Minnesota. Xiaobai has 18 years of experience in biological sciences, 10 of which in genome engineering. Xiaobai joined BMogen BioTechnologies in 2018 which was acquired by BioTechne in 2019. Xiaobai’s work at BioTechne is focused on utilizing the TcBuster™ technology to engineer custom cell lines for clients in the Cell and Gene therapy field.

Scott Silaika

Director, Commercial Business Development, Cell and Gene Therapy, Bio-techne

Scott Silaika has over 20 years of business development experience in drug development and manufacturing services, spanning from discovery through commercial, within the contract development and manufacturing (CDMO) industry. Scott’s experience includes numerous examples of identifying, leading, and supporting customer projects on high profile, mission-critical initiatives. Prior to joining Bio-Techne, Mr. Silaika held commercial development positions at AbbVie, Aesica, Albany Molecular, Avara, and Ricerca Biosciences. He earned his undergraduate degree in Chemical Engineering from Rensselaer Polytechnic Institute and his MBA from the State University at Albany.

SPEAKERS

David Hermanson
David Hermanson
Senior Manager of R&D Applications, Cell and Gene Therapy at Bio-techne
Xiaobai Patrinostro
Xiaobai Patrinostro
Manager of Genome Engineering Services, Cell and Gene Therapy at Bio-techne
Scott Silaika
Scott Silaika
Director at Bio-techne

You might also like